The BioPharm Brief: Breakthrough Signals in Cancer, Duchenne, and RNA Medicine

May 07, 07:42 PM
Headliner
Share
Subscribe

Today’s BioPharm Brief covers promising AML remission data from Aptevo, encouraging Duchenne muscular dystrophy trial results from Entrada Therapeutics, and a new GSK licensing deal expanding cardiometabolic RNA therapy development.

Share
Subscribe
Next
The BioPharm Brief: Bispecifics, Biocatalysis, and Dual-Pathway Therapies
Top episodes
The BioPharm Brief: Early Design Risks, Oncology Signals, and a Biosimilars Power Move
by The BioPharm Brief
The BioPharm Brief: Cancer, Personalized
by The BioPharm Brief
The BioPharm Brief: What’s the Big Deal About Multispecific T-Cell Engagers in Cancer and Autoimmune Diseases?
by The BioPharm Brief